Q4 2024 Earnings Call Transcript April 30, 2025 PureTech Health plc beats earnings expectations. Reported EPS is $3.98, expectations were $-2.83. Operator: Greetings and welcome to the PureTech Health ...

PureTech Health impressed the market with its annual results for 2024, as the company maintained a strong cash position while hitting a number of key clinical and regulatory milestones during the year ...

There are 1b trial data coming later this year for LYT-200 but apart from that, its only phase 3 initiations without results until late 2026-27. Seaport initiating Phase 2 trials for Anxiety ...

11:34 EDT PureTech Health (PRTC) plc – American Depositary Shares trading resumes Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks ...

11:29 EDT PureTech Health (PRTC) plc – American Depositary Shares trading halted, volatility trading pause Discover the latest stocks recommended by top Wall Street analysts, all in one place ...

2024--PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting Vistry and Frasers are among the stocks that will be ...

The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting ...

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are ...